Utama › Mieloma Pelbagai › North Carolina
Kajian klinikal Mieloma Pelbagai di North Carolina
52 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Charlotte
- dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Levine Cancer Institute, Charlotte
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05652335A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Duke University Medical Center, Durham
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Duke University Medical Center, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06500884A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Atrium Health, Charlotte
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center, Winston-Salem
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07149857A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina, Chapel Hill
- Durham VAMC, Durham
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07258511Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology, Winston-Salem
Mengambil pesertaFasa 2
Umur 60 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06052826A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
- Durham VAMC, Durham
- dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Levine Cancer Institute, Charlotte
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05201781A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Atrium Health Levine Cancer Institute, Charlotte
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07116616A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Atrium Health's Levine Cancer Institute, Charlotte
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07648264A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Medical Center, Chapel Hill
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06297226A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
- Wake Forest Baptist Health /ID# 271294, Winston-Salem
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06953960Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Novant Health Cancer Institute, Charlotte
- Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07555938HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
- Duke University Health System, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06822972Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Hillsborough
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT06375044A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chapel Hill
- GSK Investigational Site, Wilson
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Atrium Health, Levine Cancer Institute, Charlotte
- Duke University Hospital, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlotte
- Research Site, Durham
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Durham
- dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT07764978DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Mengambil peserta
Umur 60 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT06296368A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Duke Cancer Center, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- UNC Hospitals Adult Oncology Clinics, Chapel Hill
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07284758A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
- Atrium Health Wake Forest Baptist Medical Center /ID# 274847, Winston-Salem
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Jul 2026 · NCT06892522Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Duke Institute of Cancer/ Duke University, Durham
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT02343042Pre-malignant States to Hematologic Malignancies in Firefighters
- Levine Cancer Institute, Charlotte
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 49 · Semua jantina · Dikemas kini 13 Jul 2026 · NCT06870760CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- Atrium Health Levine Cancer, Charlotte
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 30 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT06644625A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina /ID# 251203, Chapel Hill
- Atrium Health Wake Forest Baptist Medical Center /ID# 251165, Winston-Salem
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- University of North Carolina at Chapel Hill, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jul 2026 · NCT05137054A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- University of North Carolina (Data Collection Only), Chapel Hill
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06083922Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- dan 4 lagi
Mengambil pesertaKajian pemerhatian
Umur 65 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT01137825Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Levine Cancer Institute, Charlotte
- Duke University, Durham
- East Carolina University, Greenville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of North Carolina, Chapel Hill
Mengambil pesertaFasa 2
Umur 19 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT06974786Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill
- Levine Cancer Institute, Charlotte
- Duke Comprehensive Cancer Center, Durham
- dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jun 2026 · NCT05145400Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Chapel Hill
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Mei 2026 · NCT06433947Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.